Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuangang Su

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
European Journal of Pharmacology|April 11, 2022
Onc201 reduces osteoclastogenesis and prevents ovariectomy-induced bone loss via inhibiting RANKL-induced NFATc1 activation and the integrin signaling pathwayLiwei Wu, Jiamin Liang, Jing Li, et al.
Phytotherapy Research : PTR|August 4, 2024
Trifolirhizin reduces osteoclast formation and prevents inflammatory osteolysis by inhibiting RANKL-induced activation of NF-κB and MAPK signaling pathways and ROSJian Huang, Dezhi Song, Minglian Xu, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|July 21, 2024
Active fraction of Polyrhachis vicina (Rogers) inhibits osteoclastogenesis by targeting Trim38 mediated proteasomal degradation of TRAF6Xiaoliang Feng, Guining Wei, Yuangang Su, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 14, 2023
Pharmacology-based molecular docking of 4-methylcatechol and its role in RANKL-mediated ROS/Keap1/Nrf2 signalling axis and osteoclastogenesisYang Xu, Dezhi Song, Yuangang Su, et al.
Life Sciences|January 24, 2020
Hederagenin protects mice against ovariectomy-induced bone loss by inhibiting RANKL-induced osteoclastogenesis and bone resorptionKun Tian, Yuangang Su, Jiaxin Ding, et al.
Frontiers in Pharmacology|February 11, 2020
Vindoline Inhibits RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss in MiceYunfei Zhan, Jiamin Liang, Kun Tian, et al.
Frontiers in Pharmacology|July 1, 2021
Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling PathwaysXue Yang, Jiamin Liang, Ziyi Wang, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 6, 2023
Isosinensetin alleviates estrogen deficiency-induced osteoporosis via suppressing ROS-mediated NF-κB/MAPK signaling pathwaysYiwu Qin, Dezhi Song, Shijie Liao, et al.
Acta Pharmaceutica Sinica. B|April 12, 2019
The epigallocatechin gallate derivative Y<sub>6</sub> reverses drug resistance mediated by the ABCB1 transporter both <i>in vitro</i> and <i>in vivo</i>Yan Wen, Ruiqiang Zhao, Pranav Gupta, et al.
Frontiers in Pharmacology|March 18, 2022
Lonafarnib Inhibits Farnesyltransferase via Suppressing ERK Signaling Pathway to Prevent Osteoclastogenesis in Titanium Particle-Induced OsteolysisLinke Huang, Weiwei Chen, Linhua Wei, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
European Journal of Pharmacology|April 11, 2022
Onc201 reduces osteoclastogenesis and prevents ovariectomy-induced bone loss via inhibiting RANKL-induced NFATc1 activation and the integrin signaling pathwayLiwei Wu, Jiamin Liang, Jing Li, et al.
Phytotherapy Research : PTR|August 4, 2024
Trifolirhizin reduces osteoclast formation and prevents inflammatory osteolysis by inhibiting RANKL-induced activation of NF-κB and MAPK signaling pathways and ROSJian Huang, Dezhi Song, Minglian Xu, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|July 21, 2024
Active fraction of Polyrhachis vicina (Rogers) inhibits osteoclastogenesis by targeting Trim38 mediated proteasomal degradation of TRAF6Xiaoliang Feng, Guining Wei, Yuangang Su, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 14, 2023
Pharmacology-based molecular docking of 4-methylcatechol and its role in RANKL-mediated ROS/Keap1/Nrf2 signalling axis and osteoclastogenesisYang Xu, Dezhi Song, Yuangang Su, et al.
Life Sciences|January 24, 2020
Hederagenin protects mice against ovariectomy-induced bone loss by inhibiting RANKL-induced osteoclastogenesis and bone resorptionKun Tian, Yuangang Su, Jiaxin Ding, et al.
Frontiers in Pharmacology|February 11, 2020
Vindoline Inhibits RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss in MiceYunfei Zhan, Jiamin Liang, Kun Tian, et al.
Frontiers in Pharmacology|July 1, 2021
Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling PathwaysXue Yang, Jiamin Liang, Ziyi Wang, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 6, 2023
Isosinensetin alleviates estrogen deficiency-induced osteoporosis via suppressing ROS-mediated NF-κB/MAPK signaling pathwaysYiwu Qin, Dezhi Song, Shijie Liao, et al.
Acta Pharmaceutica Sinica. B|April 12, 2019
The epigallocatechin gallate derivative Y<sub>6</sub> reverses drug resistance mediated by the ABCB1 transporter both <i>in vitro</i> and <i>in vivo</i>Yan Wen, Ruiqiang Zhao, Pranav Gupta, et al.
Frontiers in Pharmacology|March 18, 2022
Lonafarnib Inhibits Farnesyltransferase via Suppressing ERK Signaling Pathway to Prevent Osteoclastogenesis in Titanium Particle-Induced OsteolysisLinke Huang, Weiwei Chen, Linhua Wei, et al.
Pageof 5